In The News

Becton, Dickinson and Company Sells Rx Business to Fresenius Kabi

Practices: Securities & Public Companies, Intellectual Property Transactions, Tax, Executive Compensation & Employee Benefits, Antitrust, Life Sciences

Ropes & Gray advised Becton, Dickinson and Company (BD) in the sale of its BD Rx business, which includes a pharmaceutical manufacturing plant in Wilson, N.C., and the BD Simplist line of seven drugs in ready-to-administer prefilled glass syringes, to Fresenius Kabi USA. BD and Fresenius Kabi have also signed a 10-year supply and distribution agreement under which Fresenius Kabi will supply BD with a portfolio of intravenous solutions. Both BD and Fresenius Kabi plan to offer a range of IV solutions in the U.S. beginning in 2016.

Based in Franklin Lakes, N.J., BD is a leading medical technology company that partners with customers and stakeholders to address many of the world’s most pressing and evolving health needs.

Financial and contractual terms of the transactions, announced Jan. 8, were not disclosed.

The Ropes & Gray team included securities & public companies partner Marko Zatylny; intellectual property transactions partners Mark Bellomy and David McIntosh; tax partner David Saltzman; executive compensation & employee benefits partner Jennifer Rikoski; antitrust partner Jonathan Klarfeld; and life sciences counsel Amanda Austin

Cookie Settings